- Report
- February 2024
- 120 Pages
Asia Pacific
From €4302EUR$4,950USD£3,744GBP
- Report
- December 2024
- 159 Pages
Global
From €3433EUR$3,950USD£2,988GBP
- Report
- June 2024
- 90 Pages
United States
From €3042EUR$3,500USD£2,647GBP
- Report
- February 2024
- 115 Pages
Global
From €4128EUR$4,750USD£3,593GBP
- Report
- January 2025
- 250 Pages
Global
From €4345EUR$4,999USD£3,781GBP
- Report
- May 2024
- 160 Pages
Global
From €4319EUR$4,969USD£3,758GBP
- Report
- November 2023
- 150 Pages
Global
From €3346EUR$3,850USD£2,912GBP
€4215EUR$4,850USD£3,668GBP
- Report
- January 2025
- 21 Pages
Global
From €15639EUR$17,995USD£13,611GBP
- Report
- November 2024
- 39 Pages
Global
From €3472EUR$3,995USD£3,022GBP
- Report
- February 2023
- 1359 Pages
Global
From €2173EUR$2,500USD£1,891GBP
- Report
- May 2018
- 127 Pages
Global
From €13032EUR$14,995USD£11,342GBP
- Drug Pipelines
- July 2023
- 139 Pages
Global
From €13032EUR$14,995USD£11,342GBP
- Report
- December 2022
- 42 Pages
Global
From €3042EUR$3,500USD£2,647GBP
- Report
- February 2024
- 88 Pages
Global
From €3500EUR$4,314USD£3,153GBP
- Report
- November 2025
- 132 Pages
Global
From €826EUR$950USD£719GBP
- Report
- January 2025
- 132 Pages
Global
From €826EUR$950USD£719GBP
- Report
- April 2024
- 132 Pages
Global
From €826EUR$950USD£719GBP
- Report
- April 2024
- 132 Pages
Global
From €826EUR$950USD£719GBP

The Parkinson Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Parkinson's Disease is a progressive neurological disorder that affects movement, and is caused by a lack of dopamine in the brain. Parkinson Drugs are used to treat the symptoms of the disease, and can include levodopa, dopamine agonists, monoamine oxidase inhibitors, and catechol-O-methyltransferase inhibitors. These drugs can help to improve motor function, reduce tremors, and improve quality of life.
The Parkinson Drug market is highly competitive, with many companies offering a range of treatments. Some of the major players in the market include AbbVie, GlaxoSmithKline, Merck, Novartis, Pfizer, and Teva Pharmaceuticals. Show Less Read more